Central neurotoxicity in cancer chemotherapy: Pharmacogenetic insights

Pharmacogenomics

Volumn 12, Issue 3, 2011, Pages 379-395

  Froklage, Femke Eam ^a,b   Reijneveld, Jaap C ^a   Heimans, Jan J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

antineoplastic agents; apolipoprotein E; blood brain barrier transporter; CNS toxicity; folate metabolic pathway; methotrexate; methylenetetrahydrofolate reductase; neoplasms; organic anion transporting peptide 1A2; P glycoprotein; polymorphism

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN E; BUSULFAN; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSTATIC AGENT; DACTINOMYCIN; DIGOXIN; DOCETAXEL; DRUG METABOLIZING ENZYME; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FOLIC ACID; GLYCOPROTEIN P; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PROCARBAZINE; THIOTEPA; UNINDEXED DRUG; VINCRISTINE;

ABCB1 GENE; APOLIPOPROTEIN E GENE; ARACHNOIDITIS; ATAXIA; ATTENTION DISTURBANCE; BLOOD BRAIN BARRIER; BLURRED VISION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CATECHOL O METHYLTRANSFERASE GENE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLAR ATAXIA; CEREBELLUM DISEASE; CEREBRAL BLINDNESS; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COGNITIVE DEFECT; COMA; CONFUSION; CRANIAL NERVE PARALYSIS; DEMENTIA; DISEASE MARKER; DIZZINESS; DROWSINESS; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TRANSPORT; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; GENE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HEAD AND NECK CANCER; HUMAN; LEUKEMIA; LEUKOENCEPHALOPATHY; LONGITUDINAL STUDY; LYMPHOMA; MANIA; MEMORY; MENINGITIS; MENTAL DISEASE; MENTAL PERFORMANCE; MTHFR GENE; MYELORADICULOPATHY; NEUROMUSCULAR DISEASE; NEUROTOXICITY; OPTIC NERVE DISEASE; PARAPLEGIA; PARKINSONISM; PHARMACOGENETICS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROSPECTIVE STUDY; REVIEW; SEIZURE; SIDE EFFECT; SLCO1A2 GENE; SOMNOLENCE; SPINAL CORD DISEASE; STUPOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSPORTER GENE;

ANTINEOPLASTIC AGENTS; APOLIPOPROTEINS E; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; METABOLIC NETWORKS AND PATHWAYS; METHOTREXATE; NEOPLASMS; NEUROTOXICITY SYNDROMES; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 79953253442     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.197     Document Type: Review

References (114)

1. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ: Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63(15), 1549-1563 (2003). (Pubitemid 36976138)
2. Dietrich J, Monje M, Wefel J, Meyers C: Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 13(12), 1285-1295 (2008).
3. Ahles TA, Saykin AJ, Furstenberg CT et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Clin. Oncol, 20(2), 485-493 (2002). (Pubitemid 34072533)
4. Schagen SB, Muller MJ, Boogerd W et al.: Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients.Ann. Oncol. 13(9), 1387-1397(2002).
5. Boogerd W, Van den Bent MJ, Koehler PJ et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur. Cancer. 40(18), 2726-2733 (2004). (Pubitemid 39574724)
6. Van Dam FS, Schagen SB, Muller MJ et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. Natl Cancer Inst. 90(3), 210-218(1998). (Pubitemid 28114539)
7. Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, Van Dam FS: Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. Natl Cancer Inst. 98(23), 1742-1745 (2006). (Pubitemid 44942713)
8. Vardy J, Rourke S, Tannock IF: Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. Clin. Oncol. 25(17), 2455-2463 (2007). (Pubitemid 46999217)
9. LinnebankM, Moskau S, Jurgens A et al. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. Neuro. Oncol. 11(1), 2-8 (2009).
10. Ahles TA, Saykin AJ: Candidate mechanisms for chemotherapy-induced cognitive changes. Nat. Rev. Cancer7(3), 192-201 (2007).
11. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR: ABCBl genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. PharmacogenomicsJ. 7(3), 154-179 (2007). (Pubitemid 46794925)
12. Filley CM, Kleinschmidt-DeMasters BK: Toxic leukoencephalopathy. N. Engl J. Med. 345(6), 425-432 (2001). (Pubitemid 32750305)
13. Raffa RB: Is a picture worth a thousand (forgotten) words? Neuroimaging evidence for the cognitive deficits in 'chemo-fogV'chemo-brain'. Clin. Pharm. Ther. 35(1), 1-9(2010).
14. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF: Cognitive function in breast cancer patients receiving adjuvant chemotherapy. Clin. Oncol. 18(14), 2695-2701 (2000). (Pubitemid 30463551)
15. Schagen SB, Van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF: Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85(3), 640-650 (1999). (Pubitemid 29075285)
16. Wieneke MD, Dienst ER: Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 4(1), 61-66 (1995). (Pubitemid 26093776)
17. Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D: The effects of adjuvant chemotherapy on cognition in women with breast cancer -preliminary results of an observational longitudinal study. Breast 14(2), 142-150 (2005). (Pubitemid 40353042)
18. Bender CM, Sereika SM, Berga SL et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 15(5), 422-430 (2006). (Pubitemid 43826855)
19. Jenkins V, Shilling V, Deutsch G et al.: A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br. J. Cancer 94(6), 828-834 (2006).
20. Mehlsen M, Pedersen AD, Jensen AB, Zachariae R: No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psycho-Oncology 18(3), 248-257 (2009).
21. Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB: Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 115(8), 1776-1783 (2009).
22. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA: The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11), 2292-2299 (2004). (Pubitemid 38657875)
23. Ahles TA, Saykin AJ, McDonald 1>C et al.: Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res. Treat. 110(1), 143-152 (2008). (Pubitemid 351793851)
24. Klein M, Taphoorn MJ, Heimans JJ et al. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. Clin. Oncol. 19(20), 4037-4047(2001). (Pubitemid 32976690)
25. HildebrandJ: Neurological complications of cancer chemotherapy. Curr. Opin Oncol. 18(4), 321-324 (2006). (Pubitemid 44297240)
26. Kannarkat G, Lasher EE, Schiff D: Neurologic complications of chemotherapy agents. Curr. Opin Neurol. 20(6), 719-725 (2007). (Pubitemid 350085017)
27. Schiff D, Wen P: Central nervous system toxicity from cancer therapies. Hematol. Oncol. Clin. North Am. 20(6), 1377-1398 (2006). (Pubitemid 44768065)
28. Sioka C, Kyrksis AP: Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother. Pharmacol. 63(5), 761-767 (2009).
29. Keime-Guibert F, Napolitano M, Delattre JY: Neurological complications of radiotherapy and chemotherapy. Neurol. 245(11), 695-708 (1998). (Pubitemid 28468468)
30. Linnebank M, Pels H, Kleczar N et al.: MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology 64(5), 912-913 (2005). (Pubitemid 40316339)
31. Ackermann R, Semmler A, Maurer GD et al.: Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites. Neurooncol. 97(3), 425-427 (2010).
32. Lovblad K, Kelkar P, Ozdoba C, Ramelli G, Remonda L, Schroth G: Pure methotrexate encephalopathy presenting with seizures: CT and MRI features. Pediatr. Radiol. 28(2), 86-91 (1998). (Pubitemid 28077440)
33. Mahoney DH Jr, Shuster JJ, Nitschke R et al.: Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy. A Pediatric Oncology Group study. Clin. Oncol. 16(5), 1712-1722 (1998).
34. Reddick WE, Glass JO, Helton KJ et al.: Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNRAm. J. Neuroradiol. 26(5), 1263-1269 (2005). (Pubitemid 43821984)
35. Kiu MC, Liaw CC, Yang TS, Lai GM, Hsi SN, Lu CS: Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma. Anticancer Drugs 5(4), 480-482 (1994).
36. Bleyer WA: Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat. Rep. 65(Suppl. 1), 89-98 (1981). (Pubitemid 12160480)
37. Gagliano RG, CostanziJJ: Paraplegia following intrathecal methotrexate: report of a case and review of the literature. Cancer 37 (A), 1663-1668 (1976).
38. Kim YI: Role of the MTHFR polymorphisms in cancer risk modification and treatment. Future Oncol. 5(4), 523-542 (2009).
39. Toffoli G, De Mattia E: Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics9(9), 1195-1206 (2008).
40. Becker A, Vezmar S, LinnebankM et al.: Marked elevation in homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate. Int. J. Clin. Pharmacol. Ther. 45(9), 504-515 (2007). (Pubitemid 47408260)
41. Vezmar S, Becker A, Bode U, Jaehde U: Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49(1-2), 92-104 (2003). (Pubitemid 36469805)
42. Wagner C: Biochemical role of folate in cellular metabolism. Clin. Res. Reg. Aff. 18(3), 161-180 (2001).
43. Surtees R, Leonard J, Austin S: Association of demyelination with deficiency of cerebrospinal-fluid S-adenosylmethionine in inborn errors of methyl-transfer pathway. Lancet 338(8782-8783), 1550-1554 (1991).
44. Mahadeo KM, Dhall G, PanigrahyA, Lastra C, Ettinger LJ: Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old with acute lymphoblastic leukemia and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: homocysteine-mediated methotrexate neurotoxicity via direct endothelial injury. Pediatr. Hematol. Oncol. 27(1), 46-52 (2010).
45. Linnebank M, Malessa S, Moskau S et al.: Acute methotrexate-induced encephalopathy-causal relation to homozygous allelic state for MTRc.2756A>G (D919G)?. Chemother. 19(4), 455-457 (2007). (Pubitemid 47236526)
46. Aplenc R, Thompson J, Han P et al.: Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res. 65(6), 2482-2487 (2005). (Pubitemid 40490161)
47. De Mattia E, Toffoli G: C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur. J. Cancer 45(8), 1333-1351 (2009).
48. Kishi S, Cheng C, French D et al.: Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109(10), 4151-4157 (2007). (Pubitemid 46743376)
49. Miller JW, Ramos MI, Garrod MG, Flynn MA, Green R: Transcobalamin II 775G>C polymorphism and indices of vitamin B12 status in healthy older adults. Blood 100(2), 718-720 (2002). (Pubitemid 34761145)
50. Collin SM, Metcalfe C, Zuccolo L et al.: Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 18(9), 2528-2539 (2009).
51. Lee KM, Lan Q, Kricker A et al.: One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia. Hum. Genet. 122(5), 525-533 (2007). (Pubitemid 350148964)
52. Mahley RW, Weisgraber KH, Huang Y: Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. Lipid Res. 50(Suppl.) S183-S188 (2009).
53. Crawford FC, Vanderploeg RD, Freeman MJ et al.: APOEgenotype influences acquisition and recall following traumatic brain injury. Neurology 58(7), 1115-1118 (2002). (Pubitemid 34298559)
54. Tardiff BE, Newman MF, Saunders AM et al.: Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. Ann. Thorac. Surg. 64(3), 715-720 (1997). (Pubitemid 27435681)
55. Greenwood PM, Lambert C, Sunderland T, Parasuraman R: Effects of apolipoprotein E genotype on spatial attention, working memory, and their interaction in healthy, middle-aged adults: results From the National Institute of Mental Health's BIOCARD study. Neuropsychology 19(2), 199-211 (2005). (Pubitemid 40381656)
56. Ahles TA, Saykin AJ, Noll WW et al.: The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-Oncology 12(6), 612-619 (2003). (Pubitemid 37086736)
57. McAllister TW, Ahles TA, Saykin AJ et al.: Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments. Curr. Psychiatry Rep. 6(5), 364-371 (2004). (Pubitemid 39591817)
58. Mariani E, Polidori MC, Cherubini A, Mecocci P: Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. Chromatogr. BAnalyt. Technol. Biomed. Life Sa. 827(1), 65-75 (2005). (Pubitemid 41551598)
59. Tonelli LH, Postolache TT, Sternberg EM: Inflammatory genes and neural activity: involvement of immune genes in synaptic function and behavior. Front Biosci. 10, 675-680(2005).
60. Pusztai L, MendozaTR, Reuben JM et al.: Changes in plasma levels of inflammatory cytokines in response to paclkaxel chemotherapy. Cytokine 25(3), 94-102 (2004). (Pubitemid 38096266)
61. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D: Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br. J. Cancer 87(1), 21-27 (2002).
62. Egan MF, Goldberg TE, Kolachana BS et al.: Effect of COMrVall08/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl Acad. Sci. USA 98(12), 6917-6922 (2001). (Pubitemid 32538317)
63. Savkz J, Solms M, Ramesar R. The molecular genetics of cognition: dopamine, COA/Tand BDNF. Genes Brain Behav. 5(4), 311-328 (2006). (Pubitemid 43794814)
64. Abbott NJ: Astrocyte-endothelial interactions and blood-brain barrier permeability. Anat. 200(6), 629-638 (2002). (Pubitemid 34823054)
65. Kaal EC, Vecht CJ: The management of brain edema in brain tumors. Curr. Opin Oncol. 16(6), 593-600 (2004). (Pubitemid 39482980)
66. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158(3), 693-705 (2009).
67. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA 84(21), 7735-7738 (1987).
68. Loscher W, PotschkaH: Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 76(1), 22-76 (2005). (Pubitemid 41033402)
69. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2(1), 48-58 (2002). (Pubitemid 37328807)
70. Kerb R, Hoffmeyer S, Brinkmann U: ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2(1), 51-64 (2001). (Pubitemid 32633651)
71. Loscher W, Potschka H: Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 6(8), 591-602 (2005). (Pubitemid 41059334)
72. Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, Figg WD: Pharmacogenetics of membrane transporters: an update on current approaches. Mol. Biotechnol. 44(2), 152-167 (2010).
73. Fromm MF: Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25(8), 423-429 (2004). (Pubitemid 38981558)
74. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39, 361-398 (1999). (Pubitemid 29222564)
75. Frelet A, Klein M: Insight in eukaryotic ABC transporter function by mutation analysis. FEBSLett. 580(4), 1064-1084 (2006). (Pubitemid 43185287)
76. Loo TW, Bartlett MC, Clarke DM: Human P-glycoprotein is active when the two halves are clamped together in the closed conformation. Biochem. Biophys. Res. Commun. 395(3), 436-440 (2010).
77. Shilling RA, Venter H, Velamakanni S et al. New light on multidrug binding by an ATP-binding-cassette transporter. Trends Pharmacol. Sa. 27(4), 195-203 (2006).
78. Eichelbaum M, Fromm MF, Schwab M: Clinical aspects of the MDRl (ABCBl) gene polymorphism. Ther. DrugMonit. 26(2), 180-185 (2004). (Pubitemid 38501215)
79. Fromm MF: Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology 181-182:299-303 (2002). (Pubitemid 36015717)
80. Fromm MF: The influence of MDRl polymorphisms on P-glycoprotein expression and function in humans. Adv. DrugDeliv. Rev. 54(10), 1295-1310 (2002). (Pubitemid 35284254)
81. Kerb R: Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 234(1), 4-33 (2006). (Pubitemid 43343938)
82. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDRl (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75(1), 13-33 (2004). (Pubitemid 38130115)
83. Pauli-Magnus C, Kroetz DL: Functional implications of genetic polymorphisms in the multidrug resistance gene MDRl (ABCBl). Pharm. Res. 21(6), 904-913 (2004). (Pubitemid 38870137)
84. Sakaeda T: MDRl genotype-related pharmacokinetics: fact or fiction? DrugMetah. Pharmacokinet. 20(6), 391-414 (2005).
85. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sa. USA 97(7), 3473-3478 (2000). (Pubitemid 30183327)
86. Bankstahl JP, Loscher W: Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. Epilepsy Res. 82(1), 72-87 (2008).
87. Erdilyi DJ, Kamory E, Csokay B et al.: Synergistic interaction of ABCBl and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. PharmacogenomicsJ. 8(5), 321-327(2008).
88. Pauli-Magnus C, Feiner J, Brett C, Lin E, Kroetz DL: No effect of MDRl C3435T variant on loperamide disposition and central nervous system effects. Clin. Pharmacol. Ther. 74(5), 487-498 (2003). (Pubitemid 37357727)
89. Kotrych K, Domanski L, Gornik W, Drozdzik M: MDRl gene polymorphism in allogenic kidney transplant patients with tremor. Pharmacol. Rep. 57(2), 241-245 (2005). (Pubitemid 40778716)
90. Yamauchi A, Ieiri I, Kataoka Y et al.: Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCBl (MDRl) gene. Transplantation 74(4), 571-572 (2002).
91. Sasongko L, Link JM, Muzi M et al.: Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin. Pharmacol. Ther. 77(6), 503-514(2005). (Pubitemid 40824964)
92. Toornvliet R, Van Berckel BN, Luurtsema G et al.: Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11) C]verapamil and positron emission tomography. Clin. Pharmacol. Ther. 79(6), 540-548 (2006). (Pubitemid 43841828)
93. Kortekaas R, Leenders KL, Van Oostrom JC et al.: Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 57(2), 176-179 (2005). (Pubitemid 40179854)
94. nC]verapamil and PET. Eur. J. Clin. Pharmacol. 65(9), 941-946 (2009).
95. nC] verapamil and PET. Cereh. Blood Flow Metab. 27(2), 424-433 (2007). (Pubitemid 46148468)
96. Bartels AL, Van Berckel BN, Lubberink M, Luurtsema G, Lammertsma AA, Leenders KL: Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. ParkinsonismRelat. Disord. 14(6), 505-508 (2008).
97. Brunner M, Langer O, Sunder-Plassmann R et al.: Influence of functional haplotypes in the drug transporter gene ABCBl on central nervous system drug distribution in humans. Clin. Pharmacol. Ther. 78(2), 182-190 (2005). (Pubitemid 41112286)
98. Piwnica-Worms D, KesarwalaAH, Pichler A, Prior JL, SharmaV: Single photon emission computed tomography and positron emission tomography imaging of multi-drug resistant P-glycoprotein -monitoring a transport activity important in cancer, blood-brain barrier function and Alzheimer's disease. Neuroimaging Clin. N. Am. 16(4), 575-589 (2006). (Pubitemid 44828756)
99. LazarovaN, Zoghbi SS, Hong J et al: Synthesis and evaluation of [A-methyl-llC] A-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. Med. Chem. 51(19), 6034-6043 (2008).
100. 11C-A-desmethyl-loperamide. Nucl. Med. 51(4), 559-566 (2010).
101. nC]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. Med. Chem. 52(19), 6073-6082 (2009).
102. nC]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl. Med. Biol. 36(6), 643-649 (2009).
103. Bauer M, Karch R, Neumann F et al.: Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. Cereh. Blood Flow Metab. 30(3), 510-515 (2010).
104. la Fougere C, Boning G, Bartmarm H et al.: Uptake and binding of the serotonin 5-HTlA antagonist [F-18J-MPPF in brain of rats: Effects of the novel P-glycoprotein inhibitor tariquidar. Neuroimage 49 (2), 1406-1415 (2010).
105. nC-verapamil and PET, Nucl. Med. 50(12), 1954-1961 (2009).
106. Lee W, Glaeser H, Smith LH et al.: Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. Biol. Chem. 280(10), 9610-9617 (2005). (Pubitemid 40409657)
107. Hagenbuch B, Meier PJ: Organic anion transporting polypeptides of the OATP, SLC21 family: phylogenetic classification as OATP, SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 447(5), 653-665 (2004). (Pubitemid 38241451)
108. Kullak-Ublick GA, Hagenbuch B, Stieger B et al.: Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 109(4), 1274-1282 (1995).
109. Glaeser H, Bailey DG, Dresser GK et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. 81(3), 362-370 (2007). (Pubitemid 46364477)
110. Franke RM, Scherkenbach LA, SparreboomA: Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics 10(3), 339-344 (2009).
111. IidaA, Saito S, Sekine A et al.: Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins. Hum. Genet. 46(11), 668-683 (2001). (Pubitemid 33134745)
112. Badagnani I, Castro RA, Taylor TR et al.: Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. Pharmacol. Exp. Ther. 318(2), 521-529 (2006). (Pubitemid 44061225)
113. Van den Berg H, Van der Flier M, Van de Wetering MD: Cytarabine-induced aseptic meningitis. Leukemia 15(4), 697-699 (2001).
114. Savarese DM, Gordon J, Smith TW et al.: Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis -a case report. Cancer 77(2), 387-394 (1996). (Pubitemid 26023358)